卡维地络联合内镜下精准食管胃静脉曲张断流术治疗食管胃静脉曲张破裂出血的疗效

摘要/Abstract

摘要： 目的评估口服卡维地络联合内镜下精准食管胃静脉曲张断流术治疗食管胃静脉曲张出血患者的有效性及安全性。方法回顾性研究40例肝硬化伴食管胃静脉曲张出血患者,按治疗方法纳入内镜下精准食管胃静脉曲张断流术(ESVD)组22例,卡维地络联合ESVD组18例,重点比较两组再出血率、死亡率、内镜下改善率及并发症发生情况。结果术后2周内ESVD组和联合组再出血率分别为36.4%(8/22)、11.1%(2/18),两组间差异无统计学意义(P>0.05);而术后6月内联合组再出血率为22.2%(4/18),明显优于ESVD组54.5%(12/22),差异有统计学意义(P<0.05)。6月内两组出血相关死亡率分别为9.1%(1/22)、5.6%(1/18),总体死亡率分别为9.1%(1/22)、5.6%(1/18),差异均无统计学意义(P>0.05)。ESVD组和联合组术后1个月内镜下改善率分别为59.1%(13/22)、88.8%(16/18),术后6月分别为54.5%(12/22)、88.8%(16/18),差异均有统计学意义(P<0.05)。ESVD组和联合组随访期间无严重并发症发生。结论内镜下精准食管胃静脉曲张断流术联合卡维地络在食管胃静脉曲张出血患者中应用疗效较好、安全性高,值得临床推广。

关键词: 肝硬化, 食管胃静脉曲张破裂出血, 内镜下精准食管胃静脉曲张断流术, 卡维地络

Abstract: Objective To evaluate the clinical efficacy and safety of endoscopic selective varices devascularization (ESVD) combined with oral carvedilol in the treatment for patients with esophageal and gastric varices bleeding (EGVB). Methods A retrospective analysis was performed on 40 cirrhosis patients with EGVB. According to different methods of treatment, 22 patients were selected into ESVD group, and 18 patients were selected into carvedilol combined ESVD group, respectively. The rate of rebleeding, mortality, endoscopic improvement rate and the incidence of complications were compared between two groups. Results The rebleeding rates within 2 weeks after treatment of ESVD group and combined treatment group were 36.4% (8/22) and 11.1% (2/18), respectively, which was no significant difference (P>0.05). The rebleeding rate within 6 months after treatment of combined treatment group was 22.2% (4/18), which was significantly lower than that of ESVD group (54.5%, 12/22) (P<0.05). The rates of hemorrhage-related death within 6 months after surgery in ESVD group and combined treatment group were 9.1% (1/22) and 5.6% (1/18), respectively, and the overall mortality were 9.1% (1/22) and 5.6% (1/18), respectively, which was no statistically significant (P>0.05). One month after treatment, endoscopic improvement rates of ESVD group and combined treatment group were 59.1% (13/22) and 88.8% (16/18) respectively, which was statistically significant (P<0.05). Six months after treatment, endoscopic improvement rates of ESVD group and combined treatment group were 54.5% (12/22) and 88.8% (16/18) respectively, which was statistically significant (P<0.05). No serious complication occurred in both groups during the follow-up period. Conclusion The efficacy and safety of ESVD combined with oral carvedilol are more available in the treatment for patients with EGVB, which is worthy clinical promotion.

Key words: Liver cirrhosis, Esophageal and gastric varices bleeding, Endoscopic selective varices devascularization, Carvedilol

黎美琳, 姚上志, 王栋, 居峰, 王晓伟. 卡维地络联合内镜下精准食管胃静脉曲张断流术治疗食管胃静脉曲张破裂出血的疗效[J]. 肝脏, 2021, 26(9): 980-983.

LI Mei-lin ,YAO Shang-zhi, WANG Dong, JU Feng, WANG Xiao-wei. A study on the applycation of carvedilol combined with endoscopic selective varices devascularization in the treatment for esophageal and gastric varices bleeding[J]. Chinese Hepatolgy, 2021, 26(9): 980-983.

参考文献

[1] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 实用肝脏病杂志, 2016, 19: 641-656.
[2] 李坪, 魏红山, 蒋煜, 等. 精准贲门胃静脉曲张断流术:一次性治疗食管胃连通型静脉曲张的近期疗效. 内科急危重症杂志, 2017, 23: 284-288,329.
[3] 曹传坤, 孔德润. 内镜下精准食管胃静脉曲张断流术83例初步研究. 中华消化内镜杂志, 2018, 35: 99-104.
[4] Pagliaro L, D'Amico G, Sörensen T I , et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med, 1992, 117: 59-70.
[5] Gluud L L, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev, 2012, 8: CD004544.
[6] Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology, 2009, 50: 825-833.
[7] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393: 1597-1608.
[8] 中华医学会消化内镜学分会食管胃静脉曲张学组. 消化道静脉曲张及出血的内镜诊断和治疗规范试行方案(2009年). 中华消化内镜杂志, 2010, 27: 1-4.
[9] Sinagra E, Perricone G, D'Amico M, et al. Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther, 2014, 39: 557-568.
[10] Hobolth L, Bendtsen F, Hansen E F, et al. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. Dig Liver Dis, 2014, 46: 251-256.
[11] Bhardwaj A, Kedarisetty C K, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut, 2017, 66: 1838-1843.
[12] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62: 1634-1641.
[13] 马佳丽, 蒋煜, 艾正琳, 等. 内镜下精准食管胃静脉曲张断流术患者预后及生存状况分析. 现代消化及介入诊疗, 2019, 24: 578-582.

[1]	张云, 尹伟, 郭洪雷, 李成忠. 新型生物学标志物在肝硬化AKI早期诊断和鉴别诊断中的研究进展[J]. 肝脏, 2021, 26(9): 953-955.
[2]	潘国栋, 侯斐, 张瑶, 刘玉凤, 王晓静, 刘尧, 段英, 王艳斌, 李炜, 郝一炜, 熊号峰. 右心声学造影在肝硬化患者肺内血管分流评价中的应用[J]. 肝脏, 2021, 26(9): 972-976.
[3]	陈衍磊, 蔡永国. 超声内镜下内镜黏膜剥离术在乙型肝炎肝硬化患者食管良性肿瘤中的可行性研究[J]. 肝脏, 2021, 26(9): 984-986.
[4]	张必全, 马宇航. CT灌注相关参数定量预测血吸虫性肝硬化患者预后的价值[J]. 肝脏, 2021, 26(9): 987-989.
[5]	王开乐, 金贤德, 王甄, 张欣, 周杰. 多模态影像定量参数在肝硬化背景下小肝癌及增生结节的鉴别诊断价值[J]. 肝脏, 2021, 26(8): 861-865.
[6]	周佳美, 班志超, 张晓娟, 李艳, 张咏华, 王明蕾, 王会哲, 张欣. LSPS评分评估酒精性肝硬化并发食管胃底静脉曲张出血患者短期预后的价值[J]. 肝脏, 2021, 26(8): 874-878.
[7]	赵宏伟, 祝佳, 张国良, 白雪峰, 韩飞, 林光耀. 原发性胆汁性胆管炎患者磁共振检查肝脏表现特点分析[J]. 肝脏, 2021, 26(8): 903-906.
[8]	肖萱, 钱金李, 李婷. 自身免疫性肝炎治疗后应答不佳或不耐受的预测因素分析[J]. 肝脏, 2021, 26(8): 907-909.
[9]	张丽丽, 刘洋, 勾春燕, 胡建华. 阵发性睡眠性血红蛋白尿致布-加综合征1例并文献复习[J]. 肝脏, 2021, 26(8): 943-944.
[10]	马琳, 贾继东. 肝硬化患者营养不良、肌少症和衰弱的临床研究进展[J]. 肝脏, 2021, 26(7): 717-720.
[11]	杜谕君, 陈俊莲, 陈莉, 冯晓霞. 生长抑素对肝硬化食管胃静脉曲张破裂出血患者心电图QT间期的影响[J]. 肝脏, 2021, 26(7): 724-726.
[12]	虞晨燕, 高静雯, 殷民月, 吴爱荣, 朱锦舟, 刘晓琳. 高密度脂蛋白胆固醇预测肝硬化患者预后研究[J]. 肝脏, 2021, 26(7): 727-731.
[13]	胡豆豆, 任万雷, 仇莎, 姜相君. 肝硬化门静脉高压动物模型的实验对比研究[J]. 肝脏, 2021, 26(7): 732-736.
[14]	谢青, 王文青, 雷青芬, 闫雪华. 慢性乙型肝炎合并布鲁氏杆菌病导致肝硬化1例[J]. 肝脏, 2021, 26(7): 818-819.
[15]	顾雨玲, 韩冰, 黄沁, 甘建和, 董凤林, 许春芳, 陈友国. 妊娠合并乙肝肝硬化脾静脉破裂1例[J]. 肝脏, 2021, 26(7): 821-823.